U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H27NO3
Molecular Weight 341.444
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPAFENONE

SMILES

CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2

InChI

InChIKey=JWHAUXFOSRPERK-UHFFFAOYSA-N
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3

HIDE SMILES / InChI

Molecular Formula C21H27NO3
Molecular Weight 341.444
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB01182 | http://reference.medscape.com/drug/rythmol-propafenone-342307 | https://www.drugs.com/pro/propafenone.html | https://www.ncbi.nlm.nih.gov/pubmed/26588045

Propafenone (brand name Rythmol SR or Rytmonorm) is a class 1C anti-arrhythmic medication, which treats illnesses associated with rapid heartbeats such as atrial and ventricular arrhythmias. The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy. Propafenone is metabolized primarily in the liver. Because of its short half-life, it requires dosing two or three times daily to maintain steady blood levels. The long-term safety of propafenone is unknown. Because it is structurally similar to another anti-arrhythmic medicine, flecainide, similar cautions should be exercised in its use. Flecainide and propafenone, like other antiarrhythmic drugs, have been shown to increase the occurrence of arrhythmias (5.3% for propafenone, Teva physician prescribing information), primarily in patients with underlying heart disease. However, their use in structurally normal hearts is considered safe.

Originator

Sources: Journal of the American Geriatrics Society (1961), 9, 491-7.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RYTHMOL

Approved Use

Propafenone HCl Extended Release Capsules is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Usage Considerations: •The use of propafenone ER capsules in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use propafenone ER capsules to control ventricular rate during AF. •Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The effect of propafenone on mortality has not been determined [see BOXED WARNING

Launch Date

1989
Primary
RYTHMOL

Approved Use

Propafenone HCl Extended Release Capsules is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Usage Considerations: •The use of propafenone ER capsules in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use propafenone ER capsules to control ventricular rate during AF. •Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The effect of propafenone on mortality has not been determined [see BOXED WARNING

Launch Date

1989
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
314 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
189.94 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2900 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
322.43 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.61 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4.1%
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Other AEs: Monocyte count increased, Eosinophil count increased...
Other AEs:
Monocyte count increased (0.7%)
Eosinophil count increased (0.7%)
Platelet count decreased (0.7%)
Cardiac failure congestive (1.5%)
Coronary artery disease NOS (0.7%)
Myocardial infarction (0.7%)
Abdominal pain NOS (0.7%)
Diarrhea NOS (0.7%)
Chest pain (1.5%)
Pneumonia NOS (0.7%)
Urinary tract infection NOS (0.7%)
Prothrombin level decreased (0.7%)
Headache (0.7%)
Syncope (0.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Coronary artery disease NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Diarrhea NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Eosinophil count increased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Headache 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Monocyte count increased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Myocardial infarction 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Platelet count decreased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Pneumonia NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Prothrombin level decreased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Syncope 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Urinary tract infection NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Cardiac failure congestive 1.5%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Chest pain 1.5%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
yes
yes
yes (co-administration study)
Comment: amiodarone and tobacco (CYP1A2 inhibitor) can be expected to cause increased plasma levels of propafenone
yes
yes (co-administration study)
Comment: ketoconazole, erythromycin, saquinavir, and grapefruit juice for (CYP3A4 inhibitors) can be expected to cause increased plasma levels of propafenone; The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 sinhibition with the simultaneous administration of propafenone may significantly increase the concentration of propafenone and thereby increase the risk of proarrhythmia and other adverse event
yes
yes (pharmacogenomic study)
Comment: Multiple studies have found that genetic variants in the CYP2D6 gene influence the plasma drug levels of propafenone
Tox targets
PubMed

PubMed

TitleDatePubMed
Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel.
2001 Apr
Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.
2001 Apr
Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers.
2001 Dec
[Clinical and experimental study of effect of yangxin fumai oral liquid in treating patients with extrasystole].
2001 Feb
[The best in 2000 on arrhythmia].
2001 Jan
Intravenous antiarrhythmic agents.
2001 Jan
[Acute cholestatic hepatitis caused by propafenone. Report of a case and review of the literature].
2001 Mar
Global distribution of atrial ectopic foci triggering recurrence of atrial tachyarrhythmia after electrical cardioversion of long-standing atrial fibrillation: a bi-atrial basket mapping study.
2001 Mar 1
The effect of propafenone on premature ventricular contractions (PVC): an analysis based on heart rate dependency of PVCs.
2001 Nov
Late-breaking clinical trials at the American Heart Association's scientific sessions 2001.
2001 Nov 20
Stereoselective metabolism of propafenone by human liver CYP3A4 expressed in transgenic Chinese hamster CHL cells lines.
2001 Oct
Transient outward current inhibition by propafenone and 5-hydroxypropafenone in cultured neonatal rat ventricular myocytes.
2001 Sep
Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.
2001 Sep 15
[Atrial fibrillation. New views on an old disease].
2001 Sep-Oct
[Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone].
2002
Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
2002
How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation.
2002 Aug
Congenital junctional ectopic tachycardia in children and adolescents: a 20 year experience based study.
2002 Aug
[Role amiodarone in sinus rhythm maintenance after successful cardioversion in patients with chronic non-valvular atrial fibrillation].
2002 Dec
Propafenone-related cholestatic hepatitis in an elderly patient.
2002 Jul
[Proarrhythmic effects of propafenone in a woman with hepatopathy: is it always a simple drug in clinical practice?].
2002 Jul
Amiodarone: pearl or peril?
2002 Jul
[Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study].
2002 Jun
Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
2002 Nov
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
2002 Nov
New insights into the mechanisms and management of atrial fibrillation.
2002 Oct 29
[Hepatic toxicity of propafenone: a case description].
2002 Oct-Dec
Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.
2002 Sep
Long-term follow-up of sudden cardiac arrest survivors and electrophysiologically guided antiarrhythmic therapy.
2003
High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes.
2003 Aug
[Clinical heart arrest after emergency "direct current" cardioversion of atrial flutter].
2003 Feb 3
Class I or class III agents for atrial fibrillation: are asking the right question?
2003 Jul
Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter.
2003 Jul
A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord.
2003 Jul 25
Unintentional pediatric overdose of propafenone.
2003 Jul-Aug
[Drug therapy of atrial fibrillation].
2003 Jun 15
Effects of a series of dihydroanthracene derivatives on drug efflux in multidrug resistant cancer cells.
2003 Mar
Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study).
2003 Mar
Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
2003 Mar
Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1.
2003 Mar
Excitable gap composition in the presence of antiarrhythmic drugs in common human atrial flutter.
2003 Mar 15
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches.
2003 Mar 20
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
2003 Mar 20
Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts.
2003 May 2
Patents

Sample Use Guides

Initiate therapy with 150 mg given every 8 hours. As needed, uptitrate in 3-4 days to 225-300 mg every 8 hours
Route of Administration: Oral
Hela cells were used for activity evaluation. Proliferation percentage was determined by the SRB assay. Cells were incubated with the Propafenone at the concentrations of 0.005-0.2 g/L for 48 h, and the cell proliferation/viability was determined using the survival percentage with the cells treated only with dimethyl sulfoxide (DMSO) at 0.1% as a reference
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:38 GMT 2023
Edited
by admin
on Fri Dec 15 15:30:38 GMT 2023
Record UNII
68IQX3T69U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROPAFENONE
INCI   INN   MI   VANDF   WHO-DD  
INN   INCI  
Official Name English
PROPAFENONE [MI]
Common Name English
PROPAFENON HEXAL
Brand Name English
PROPAFENONE [INCI]
Common Name English
PROPAFENONE [VANDF]
Common Name English
Propafenone [WHO-DD]
Common Name English
propafenone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
LIVERTOX NBK548005
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
NDF-RT N0000175426
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
NCI_THESAURUS C47793
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
WHO-VATC QC01BC03
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
WHO-ATC C01BC03
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID9045184
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
DRUG BANK
DB01182
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
IUPHAR
2561
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
DRUG CENTRAL
2291
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
ECHA (EC/EINECS)
258-955-6
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
WIKIPEDIA
PROPAFENONE
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL631
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
FDA UNII
68IQX3T69U
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
LACTMED
Propafenone
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
PUBCHEM
4932
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
RXCUI
8754
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY RxNorm
CAS
54063-53-5
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
SMS_ID
100000081149
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
CHEBI
63619
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
HSDB
7929
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
INN
3312
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
MERCK INDEX
m9178
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY Merck Index
MESH
D011405
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
NCI_THESAURUS
C61909
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
DAILYMED
68IQX3T69U
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
EVMPD
SUB10094MIG
Created by admin on Fri Dec 15 15:30:38 GMT 2023 , Edited by admin on Fri Dec 15 15:30:38 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
METABOLIC ENZYME -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Population
PHARMACOKINETIC